Investing Profile

Ali Behbahani

VCInvestor
General Partner at New Enterprise Associates (NEA)
nea.com/team/ali-behbahani-mdPhiladelphia, Pennsylvania
Photo of Ali Behbahani, General Partner at New Enterprise Associates (NEA)

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
$2.0M - $50.0M
$25.0M
18
$6.2B
CompanyStageDateRound SizeTotal Raised
Nexo Therapeutics
Series AJul 2023$60M
$60M
Co-investors: Carlo Rizzuto (Versant Ventures)
Launchpad Therapeutics
Series ADec 2022$30M
$30M
Co-investors: Alexander Mayweg (Versant Ventures)
Tune Therapeutics
Series ADec 2021$40M
$40M
858 Therapeutics
Series ASep 2021$60M
$60M
Co-investors: Clare Ozawa (Versant Ventures)
Stablix
Series AJun 2021$63M
$63M
Co-investors: Carlo Rizzuto (Versant Ventures)
Monte Rosa Therapeutics
Series CMar 2021$95M
Series BSep 2020$96M
Series AMay 2020$33M
$220M
Co-investors: Markus Warmuth (Versant Ventures), Alexander Mayweg (Versant Ventures), Andrew Schiff (Aisling Capital)
Spyglass Ophthalmics
Series BJan 2021$28M
Series AMay 2019
$28M
Co-investors: Tak Cheung (New Enterprise Associates (NEA)), Cynthia Yee (Vensana Capital)
Rotation Medical
Series BAug 2016$12M
Series BJul 2014$27M
$39M
Co-investors: Fouad Azzam (EQT Life Sciences), Scott Weiner (Amzak Health Investors)